320 related articles for article (PubMed ID: 9764815)
1. Effective combined immunochemotherapy with dinitrochlorobenzene and fotemustine in skin and brain metastases of melanoma.
Göring HD; Zierner A; Kröning Y; Trebing D; Kämpgen E; Bröcker EB
Melanoma Res; 1998 Aug; 8(4):379. PubMed ID: 9764815
[No Abstract] [Full Text] [Related]
2. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
3. [Acquired myelodysplastic syndromes after treatment of melanoma with fotemustine and dacarbazine].
Perrot JL; Lanthier K; Benoit F; Graille MC; Guy C; Bertheas MF; Cambazard F
Ann Dermatol Venereol; 1995; 122(10):663-6. PubMed ID: 8687048
[TBL] [Abstract][Full Text] [Related]
4. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study.
Avril MF; Aamdal S; Grob JJ; Hauschild A; Mohr P; Bonerandi JJ; Weichenthal M; Neuber K; Bieber T; Gilde K; Guillem Porta V; Fra J; Bonneterre J; Saïag P; Kamanabrou D; Pehamberger H; Sufliarsky J; Gonzalez Larriba JL; Scherrer A; Menu Y
J Clin Oncol; 2004 Mar; 22(6):1118-25. PubMed ID: 15020614
[TBL] [Abstract][Full Text] [Related]
5. [Fotemustine in the treatment of metastatic malignant melanoma. Overall analysis of results].
Pathol Biol (Paris); 1990 Oct; 38(8):876-80. PubMed ID: 2274396
[No Abstract] [Full Text] [Related]
6. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
[TBL] [Abstract][Full Text] [Related]
7. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma.
Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Bui BN; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre ME; De Gislain C; Bensadoun RJ; Clavel M
Melanoma Res; 2003 Feb; 13(1):97-103. PubMed ID: 12569292
[TBL] [Abstract][Full Text] [Related]
9. [Association of radiation- and fotemustine-therapy in the management of brain metastases from non-small-cell cancers of the lung].
Pignon T; Astoul P; Ruggieri S; Vialette JP; Orabona P; Muracciole X; Boutin C; Juin P
Bull Cancer Radiother; 1994; 81(1):49-51. PubMed ID: 7893524
[No Abstract] [Full Text] [Related]
10. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma.
Gill S; Shapiro J; Westerman D; Prince HM
J Clin Oncol; 2007 Oct; 25(28):4493-4. PubMed ID: 17906211
[No Abstract] [Full Text] [Related]
11. Multicenter phase II trial of the single agent fotemustine in patients with advanced malignant melanoma.
Calabresi F; Aapro M; Becquart D; Dirix L; Wils J; Ardizzoni A; Gerard B
Ann Oncol; 1991 May; 2(5):377-8. PubMed ID: 1954183
[No Abstract] [Full Text] [Related]
12. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.
Jacquillat C; Khayat D; Banzet P; Weil M; Avril MF; Fumoleau P; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
Cancer Chemother Pharmacol; 1990; 25(4):263-6. PubMed ID: 2403853
[TBL] [Abstract][Full Text] [Related]
13. Neurological toxicity during metastatic melanoma treatment with fotemustine.
Khalil Z; Pageot N; Carlander B; Guillot B
Melanoma Res; 2005 Dec; 15(6):563-4. PubMed ID: 16314745
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine given simultaneously with total brain irradiation in multiple brain metastases of malignant melanoma: report on a pilot study.
Bröcker EB; Bohndorf W; Kämpgen E; Trcka J; Messer P; Tilgen W; Engenhart K; Flentje M
Melanoma Res; 1996 Oct; 6(5):399-401. PubMed ID: 8908601
[TBL] [Abstract][Full Text] [Related]
15. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma.
Khayat D; Avril MF; Gerard B; Bertrand P; Bizzari JP; Cour V
Melanoma Res; 1992 Sep; 2(3):147-51. PubMed ID: 1450667
[TBL] [Abstract][Full Text] [Related]
16. Fotemustine with or without dacarbazine for brain metastases of malignant melanoma.
Merimsky O; Inbar M; Reider-Groswasser I; Chaitchik S
Eur J Cancer; 1991; 27(8):1066. PubMed ID: 1832900
[No Abstract] [Full Text] [Related]
17. Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.
Ulrich J; Gademann G; Gollnick H
J Neurooncol; 1999 Jun; 43(2):173-8. PubMed ID: 10533730
[TBL] [Abstract][Full Text] [Related]
18. Medical treatment and other combination regimens.
Bajetta E; Del Vecchio M; Bajetta R; Canova S
Tumori; 2007; 93(3):suppl 22-6. PubMed ID: 17679485
[No Abstract] [Full Text] [Related]
19. [Randomised phase III trial of fotemustine versus fotemustine plus whole brain irradiation in cerebral metastases of melanoma].
Mornex F; Thomas L; Mohr P; Hauschild A; Delaunay MM; Lesimple T; Tilgen W; Nguyen BB; Guillot B; Ulrich J; Bourdin S; Mousseau M; Cupissol D; Bonneterre J; de Gislain C; Bensadoun JR; Clavel M
Cancer Radiother; 2003 Feb; 7(1):1-8. PubMed ID: 12648711
[TBL] [Abstract][Full Text] [Related]
20. Severe neurological disabilities after complete remission of advanced malignant melanoma following fotemustine therapy in combination with total brain irradiation.
Gruss C; Geissler A; Schalke B; Landthaler M; Stolz W
Melanoma Res; 2002 Aug; 12(4):403-4. PubMed ID: 12170192
[No Abstract] [Full Text] [Related]
[Next] [New Search]
